We have observed a clear development path for the companies that have evolved into the current leadership class of the cannabis space, and OrganiGram Holdings Inc (OTCMKTS:OGRMF) is starting to show signs of emerging in a similar manner. One of the key elements in this high-free-cash-flow type of industry is strategic investment and diversification. We have continually noted this in both Aurora and Canopy. And now we are starting to see some similar moves from Organigram.
For example, the company just announced that it has, through its wholly-owned subsidiary 10870277 Canada Inc., executed an investment agreement dated as of October 10, 2018 with alpha-cannabis Pharma GmbH pursuant to which the Purchaser will acquire 8,333 common shares of ACG, representing a 25% stake in the capital of ACG, for aggregate proceeds of €1,625,000. According to the release, the closing is subject to certain formalities under German law largely of an administrative nature.
OrganiGram Holdings Inc (OTCMKTS:OGRMF) casts itself as a company that produces and sells medical marijuana to individuals and physicians in Canada. It offers marijuana plants, seeds, and cuttings; cannabis oil; and dried flower and cannabis.
The company sells its products through phone and online store. It also operates healing centers that offer treatments for post-traumatic stress disorders, chronic pain, and trauma therapy. In addition, the company exports its products.
OrganiGram Holdings Inc. was founded in 2013 and is based in Moncton, Canada.
Moreover, OrganiGram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, OrganiGram Inc., is a licensed producer of medical marijuana in Canada. OrganiGram is focused on producing the highest quality, condition-specific medical marijuana for patients in Canada.
OGRMF’s facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations.
According to company materials, “From the day we started back in 2013, it’s been about making lives better – for our clients, our people, and our community. We’re based in Moncton, New Brunswick, the heart of the Maritimes, but at OrganiGram Holdings we’re committed to improving the quality of life for Canadians across the country. For us, this means working with health-care providers and industry organizations, supporting research and education, and providing a safe, effective product. To be effective in that last goal, we made a decision to produce organic cannabis. Growing certified organic medical cannabis isn’t easy, in fact, most licensed producers won’t take this on. It means more care, more testing, more rules… but in the end, it means a product that we feel delivers on our goals in the best way. And improving the quality of life for Canadians is not just about getting safe, quality product to them effectively. It’s about creating jobs, being good neighbors and contributing to our community.”
Find out when $OGRMF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, OGRMF just announced that it has, through its wholly-owned subsidiary 10870277 Canada Inc., executed an investment agreement dated as of October 10, 2018 with alpha-cannabis Pharma GmbH pursuant to which the Purchaser will acquire 8,333 common shares of ACG, representing a 25% stake in the capital of ACG, for aggregate proceeds of €1,625,000.
In all, we’ve witnessed about -10% piled on for shareholders of the company during the trailing month. In addition, the listing has seen interest climb, with an increase in recent trading volume of 94% beyond its prior sustained average level.
“As we continue to build the framework of our international medical business, finding the right partners in the right markets has been a priority for our company,” stated Greg Engel, CEO at Organigram. “This relationship is a perfect example of two companies coming together towards a common goal, and we’re very excited to build our business in Germany through our partners at alpha-cannabis® Pharma GmbH”
Currently trading at a market capitalization of $564.26M, OGRMF has a significant war chest ($155.8M) of cash on the books, which must be weighed relative to about $9.1M in total current liabilities. OGRMF is pulling in trailing 12-month revenues of $12.2M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 94.3%. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $OGRMF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $OGRMF, either long or short, and we have not been compensated for this article.